Lyra Therapeutics Inc LYRA.OQ LYRA.O is expected to show no change in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2025
The Watertown Massachusetts-based company is expected to report a 0.0% equal in revenue to $195 thousand from $195 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Lyra Therapeutics Inc is for a loss of $5.25 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Lyra Therapeutics Inc is $23.00, about 78.7% above its last closing price of $4.90
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -5.67 | -6.02 | -5.51 | Beat | 8.5 |
Mar. 31 2025 | -7.50 | -6.83 | -6.00 | Beat | 12.2 |
Dec. 31 2024 | -6.26 | -6.00 | -8.00 | Missed | -33.3 |
Sep. 30 2024 | -10.46 | -11.40 | -9.00 | Beat | 21.1 |
Jun. 30 2024 | -16.42 | -16.40 | -37.00 | Missed | -125.6 |
Mar. 31 2024 | -13.32 | -13.10 | -17.50 | Missed | -33.6 |
Dec. 31 2023 | -15.75 | -11.00 | Beat | 30.2 | |
Sep. 30 2023 | -15.51 | -15.90 | -13.50 | Beat | 15.1 |
This summary was machine generated November 7 at 14:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)